SMU-R39

SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM) . SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180) -induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis[1].

Product Specifications

UNSPSC

12352005

Target

NF-κB; p38 MAPK; Toll-like Receptor (TLR)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

OC1=CC=C(N2C=NC3=C2C4=CC=CC=C4N=C3N5CCN(CC)CC5)C=C1C

Molecular Formula

C23H25N5O

Molecular Weight

387.48

References & Citations

[1]Wu P, et al. Structure-based rational design of TLR7/8 antagonists through agonist scaffold reengineering for psoriasis therapy. Eur J Med Chem. 2025 Dec 5;299:118063.